Bernstein SocGen Group analyst Jeffrey Walch upgraded Summit Therapeutics plc (NASDAQ: SMMT) from Underperform to Market Perform with a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Upgrades